Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Modification of Psoriasis by Selective IL-23 Blockade Using Risankizumab

NCT04630652 is registered in ClinicalTrials.gov with Jaehwan Kim as lead sponsor.

NCT NCT04630652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04630652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Modification of Psoriasis by Selective IL-23 Blockade Using Risankizumab
Lead sponsor
Jaehwan Kim
Phase
Phase 4
Overall status
Completed
Start date
April 7, 2021
Completion date
May 13, 2025
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis